Mar 14, 2019

Pancreatic Cancer Update – Part 2: Our interview with Dr Chiorean highlights the following topics as well as cases from her practice:

• Biomarker-driven and molecular-targeted therapies for patients with adenocarcinoma of the pancreas: 0m0s
• Rationale for the investigation of PEGPH20 in combination with pembrolizumab for previously treated hyaluronic acid (HA)-high metastatic pancreatic cancer: 4m40s
• Tolerability and quality of life with PEGPH20 in combination with chemotherapy; mitigation of associated thromboembolic events: 6m59s
• Ongoing Phase II trial of PEGPH20 with pembrolizumab for previously treated HA-high metastatic pancreatic ductal adenocarcinoma: 10m14s
• Testing for emerging biomarkers (eg, microsatellite instability) of response to immune checkpoint inhibitors in metastatic pancreatic cancer: 11m49s
• Incidence of germline BRCA mutations and response to PARP inhibition: 15m27s
• Case: A 55-year-old woman presents with back pain and dyspepsia and is diagnosed with borderline resectable adenocarcinoma of the pancreas: 17m55s
• Risk of relapse with and without adjuvant chemotherapy for patients with lymph node involvement: 24m45s
• Clinical experience with adjuvant FOLFIRINOX and gemcitabine/nab paclitaxel: 29m46s
• Activity, tolerability and dosing of adjuvant FOLFIRINOX: 31m39s
• Role of neoadjuvant chemotherapy in the treatment of resectable or borderline resectable adenocarcinoma of the pancreas: 33m55s
• Case: A 69-year-old woman with metastatic pancreatic cancer receives nal-IRI/5-FU/LV after experiencing disease progression on gemcitabine/nab paclitaxel: 38m26s
• Response and tolerability with FOLFIRINOX compared to gemcitabine/nab paclitaxel: 41m49s
• Second-line therapy options for metastatic pancreatic cancer: 46m59s
• SWOG-S1513: An ongoing Phase II trial evaluating FOLFIRI alone versus modified FOLFIRI with the PARP inhibitor veliparib as second-line therapy for metastatic pancreatic cancer: 50m42s
• Investigation of CDK4/6 inhibition-based therapies for advanced pancreatic cancer: 52m21s
• Second opinion: A 53-year-old man of Ashkenazi Jewish descent with a strong family history of BRCA mutation-associated cancers presents with metastatic pancreatic cancer and is found to harbor a germline BRCA2 mutation: 54m34s
• Importance of palliative care in managing the symptoms of pancreatic cancer: 1h1m22s

Select publications